Hyperlipidemia is generally characterized by increased fasting concentrations of total cholesterol, lowdensity lipoprotein (LDL) cholesterol, and triglyceride, in conjunction with decreased concentrations of highdensity lipoprotein (HDL) cholesterol. 1) Evidence from human clinical and epidemiologic studies suggests that hyperlipidemia is one of the most important modifiable risk factors for coronary heart disease. 2, 3) Its prevention and therapy should therefore be a worldwide priority, and numerous studies of agents beneficial in its treatment, including drugs, 4, 5) natural products, 6, 7) and foods, 8, 9) have been reported. Spontaneously hyperlipidemic (SHL) mice, established by inbreeding of Japanese wild mice (Mus musculus molossinus), have high plasma cholesterol due to disruption of the apolipoprotein E (apoE) gene. 10) ApoE, a component of all lipoproteins except for LDL, functions as a ligand for receptors to clear chylomicron and very low-density lipoprotein (VLDL) remnants. Hence, apoE-deficient mice demonstrate high plasma cholesterol levels and are often used as popular model of atherosclerosis.
11) C57BL/6.KOR-ApoE shl mice, congenic SHL mice with a genetic background of C57BL/6, also have high serum cholesterol, and they demonstrate the most severe atherosclerosis among SHL and other congenic SHL mice (the genetic background of BALB/c and C3H/He). 12) The persimmon, also known as kaki, is a major fruit in China, Korea, and Japan. In recent years, the attention of some researchers has been focused on persimmon fruits and their peels. 13, 14) Because Gifu Prefecture is a primary production area of persimmon in Japan, we studied the physiological effects of persimmon on mice, and found that young persimmon fruit (YP), but not the matured fruit, prevented fatty liver and rises in plasma lipids, including total cholesterol, LDL cholesterol, and triglyceride, in a dietinduced murine obesity model. 15) Hence YP is thought to be beneficial in the development of preventive agents against hyperlipidemia, but the ameliorative effects of YP on genetically determined hyperlipidemia have not been proved. To examine whether YP can improve genetically determined hyperlipidemia, we y To whom correspondence should be addressed. Tel: +81-574-25-3803; Fax: +81-574-25-3804; E-mail: matsumoto@bio.rd.pref.gifu.jp Abbreviations: ABCA1, ATP binding cassette transporter A1; apoE, apolipoprotein E; CR, C57BL/6.Cr mice; CYP7A1, cholesterol 7-hydroxylase; EF-1, elongation factor-1; EWAT, epididymal white adipose tissue; FAS, fatty acid synthetase; FXR, farnesoid X receptor; HDL, high density lipoprotein; HE, hematoxylin and eosin; HMGCoAR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; HPLC, high-performance liquid chromatography; LDL, low density lipoprotein; LDL-R, low density lipoprotein receptor; LXRs, Liver X receptors; MP, mature persimmon fruit; SCD-1, stearoyl-CoA desaturase-1; SHL, spontaneously hyperlipidemic; SHL-C, C57BL/6.KOR-ApoE shl mice fed a basal diet; SHL-YP, C57BL/6.KOR-ApoE shl mice fed a diet supplemented with young persimmon fruit; SHP, small heterodimer partner; SREBP, sterol regulatory element-binding protein; VLDL, very low density lipoprotein; YP, young persimmon fruit investigated the effects of YP on C57BL/6.KORApoE shl mice.
Materials and Methods
Diets. A commercially purchased CE-2 diet (Clea Japan, Tokyo) was used as the basal diet in this study. Young persimmon fruits (YPs), Hachiya-kaki, (with peel and seeds, but without calyx) were dried by storage at a temperature below 42 C using a decompression machine (BCD-2000U; Yahiro Industries, Minokamo, Japan), and then powdered. Dried and powdered YP was added to the basal diet at a concentration of 5% (w/w). The nutritional data for each experimental diet are shown in Table 1 . The data for YP were analyzed by the Food Analysis Technology Center SUNATEC (Yokkaichi, Japan). Total calories were calculated according to the nutrition standards of the Ministry of Health, Labor and Welfare of Japan (2003).
Animals. Five-week-old male mice (C57BL/6.KORApoE shl and C57BL/6.Cr strains) were purchased from Japan SLC (Hamamatsu, Japan). After 1 week of breeding, the C57BL/6.KOR-ApoE shl mice were randomly assigned to two groups of five, housed individually, and fed the basal diet or the diet supplemented with YP for 10 weeks. C57BL/6.Cr (n ¼ 5) mice were also housed individually and fed the basal diet. C57BL/ 6.Cr mice were designated as CR, C57BL/6.KORApoE shl mice fed the basal diet as SHL-C, and C57BL/ 6.KOR-ApoE shl mice fed the diet supplemented with YP as SHL-YP, respectively. After anesthetization with CO 2 gas with fasting for 14 h, the mice were sacrificed and their organs were dissected for analysis.
All the experiments were performed in conformation with the International Guiding Principles for Biomedical Research Involving Animals (1985) .
Hepatic cholesterol and triglyceride. Total lipids were extracted from 30-60 mg aliquots of liver by the Bligh and Dyer method, 16) and dissolved in isopropanol. Hepatic total cholesterol and triglyceride were analyzed using Cholesterol E and Triglyceride E kits (Wako Pure Chemical, Osaka, Japan), respectively.
Histopathology of liver. Dissected liver samples were fixed with 4% paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) overnight at 4 C. After rinsing with phosphate-buffered saline, the samples were dehydrated and embedded in paraffin wax. Paraffin sections were prepared using a microtome, followed by hematoxylin and eosin (HE) staining. The prepared specimens were observed with a BX50 microscope (Olympus, Tokyo, Japan).
Blood chemistry. Plasma lipoproteins were analyzed by an on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides by highperformance liquid chromatography (HPLC) at Skylight Biotech (Akita, Japan), according to the procedure described by Usui et al. 17) Plasma glucose was measured using a Glucose CII kit (Wako Pure Chemical).
Fecal bile acid concentration. Feces were collected for 48 h at 9 weeks after treatment. The collected feces were freeze-dried, and then their bile acid was extracted with 90% ethanol at 65 C for 4 h. The bile acid concentration was analyzed using a bile acid kit (Kyokuto Pharmaceutical Industries, Takahagi, Japan).
Quantitative real-time RT-PCR. Total RNA samples were isolated from liver tissues using a QuickPrep Total RNA extraction kit (GE Healthcare, Piscataway, NJ). For preparation of cDNA, 2 mg of each total RNA sample was reverse-transcribed using Super Script III Rnase H À -reverse transcriptase (Invitrogen, Carlsbad, CA) and oligo(dT) primers (Invitrogen). The prepared cDNA samples were then purified using a PCR Purification kit (Qiagen, Cambridge, MA). Quantitative real-time PCR was performed on a BioFlux LineGene machine (Toyobo, Osaka, Japan) using a SYBR Green Real-time PCR Master Mix (Toyobo) according to the manufacturer's instructions. A housekeeping transcript, elongation factor-1 (EF-1), was used as an internal control because of its stable expression in vivo.
18) The primers used for the various genes are summarized in Table 2 . Primers for Liver X receptors (LXRs) detect both LXR and LXR subtypes. The PCR products were evaluated by inspection of their melting curves (data not shown).
Western blot analysis. Total proteins were extracted from 10-30 mg aliquots of liver. Each sample was homogenized with chilled lysis buffer containing 10 mM Tris-HCl (pH 7.4), 1% NP-40, 0.1% deoxycholic acid, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, and a Protease inhibitor cocktail (Roche, Mannheim, Germany), and kept for 30 min on ice. After centrifugation at 140,000 rpm for 20 min at 4 C, the resulting supernatant was collected as the total protein sample. Protein content was measured with a BCA Protein Assay Reagent (Pierce, Rockford, IL). Twenty mg of each protein sample was used in Western blot analysis using rabbit polyclonal anti-LDL receptor antibody (Cayman, Ann Arbor, MI) and donkey anti-rabbit IgG secondary antibody (GE Healthcare). The ECL plus Western blotting detection system (GE Healthcare) was used in visualization of the signal. For detection of -actin, an internal control, the membrane was re-probed with a Restore Western Blot Stripping Buffer (Pierce), and then Western blot analysis was performed using rabbit polyclonal anti--actin antibody (BioLegend, San Diego, CA).
Statistics. A Tukey-Kramer or un-paired t-test was performed with Stat view software (SAS Institute, Cary, NC).
Results
Young persimmon fruit ameliorates hyperlipidemia All animals were in good health throughout the experiment, and no side effects, such as diarrhea, were apparent (data not shown).
To determine whether YP can improve genetically determined hyperlipidemia, C57BL/6.KOR-ApoE shl mice were fed a diet with (SHL-YP) and without (SHL-C) dried and powdered YP at a concentration of 5% (w/w). We also used C57BL/6.Cr mice (CR), which have the same genetic background as C57BL/6.KORApoE shl mice, to examine the characteristics of the SHL-C mice. Table 3 compares various physiological parameters in the CR, SHL-C, and SHL-YP groups. Although the total energy intake of the SHL-C group was significantly higher than that of the CR group, the developments of their body weights ( Fig. 1) and body weight gains after 10 weeks of treatment were almost the same as for the CR group. No significant difference was observed in liver weights, while the kidney weight/ body weight of the SHL-C group was larger than that of the CR group. The hepatic cholesterol and triglyceride contents of the SHL-C group were significantly higher than those of the CR group, but the epididymal white adipose tissue (EWAT) of the SHL-C group was very small as compared to that of the CR group. HE staining showed that the hepatocytes of the CR group had small lipid droplets in their cytoplasm, especially in zone 3 (centrilobular area), while in the hepatocytes of the SHL-C group, the cytoplasm filled with small lipid droplets in both zone 1 (peripheral area) and zone 3, indicating that diffuse fatty liver occurred in the SHL-C group (Fig. 2) . In the plasma lipid analysis, cholesterol profiles in the lipoproteins were analyzed by HPLC (Fig. 3A) . The SHL-C group exhibited apparently higher cholesterol levels in total plasma, chylomicron, very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) (Fig. 3B ). This high content of plasma cholesterol might have bad effect on their kidneys, leading to a hypertrophic condition. Despite the huge elevation of plasma total cholesterol, the SHL-C group had lower high-density lipoprotein (HDL) cholesterol levels than the CR group (Fig. 3B) . These results suggest that the C57BL/6.KOR-ApoE shl mouse is a representative model of non-obese hyperlipidemia. Table 3 shows some differences in the liver between the SHL-C group and the SHL-YP group. The SHL-YP group showed a smaller proportion of liver weight/body weight than the SHL-C group, but the hepatic triglyceride content of the SHL-YP group was 1.3-hold higher than that of the SHL-C group. As for the histopathological observations, slightly more small lipid droplets in the cytoplasm were observed in the hepatocytes of the SHL-YP group than in those of the SHL-C group, while large lipid droplets, inflammation, and fibrosis were not observed in either the SHL-C group or the SHL-YP group (Fig. 2) . Because hepatic triglyceride is known to be associated with insulin resistance, 19) we also measured fasting plasma glucose. As Fig. 4 shows, there were no significant differences in the fasting plasma glucose level among the groups. On the other hand, YP exerted a significant hypolipidemic effect on the C57BL/6.KORApoE shl mice (Fig. 3) . Although the data for the two groups varied, cholesterol levels in total (641:
/dl, P < 0:05) in the plasma were significantly lower in the SHL-YP group than in the SHL-C group (Fig. 3B) . HDL cholesterol was also lower in the SHL-YP group than in the SHL-C group, but there was no statistical significance between them, and their percentages of total cholesterol were almost the same (SHL-C, 5.0%, and SHL-YP, 5.9%).
Fecal bile acid excretion
Conversion of cholesterol to bile acid plays an important role in cholesterol homeostasis, and the initial and rate-limiting enzyme, cholesterol 7-hydroxylase (CYP7A1), regulates bile acid synthesis. 20) Hypocholesterolemic bile acid-binding resins and ileal bile acid transporter inhibitors have been known to induce CYP7A1 in the liver. 21, 22) Our previous study also showed a significant increase (3-fold) in hepatic CYP7A1 gene expression in mice fed a diet containing 10% (w/w) of YP, 15) suggesting that acceleration of fecal bile acid excretion is the major mechanism of the hypolipidemic effect due to YP. Hence we examined the amount of fecal bile acid after YP intake (Fig. 5A) . Fecal bile acid increased 1.6-fold due to YP intake (SHL-C, 3:42 AE 0:27; SHL-YP, 5:55 AE 0:67 mmol/2 d, P < 0:001), and this response was not accompanied by a proportional elevation in the amount of feces (Fig. 5B) , indicating that the bile acid concentration in the feces increased.
Gene expression analysis in the liver
The liver plays a central role in lipid metabolism, including synthesis, storage, and degradation. Treatment of hypolipidemic agents affects the expression of hepatic genes related to lipid metabolism. Hence we performed SYBER green-based real time RT-PCR on the liver to compare the expression levels of lipid metabolismrelated genes as between the SHL-C group and the SHL-YP group in order to clarify the molecular mechanisms underlying the metabolic changes induced by intake of YP (Fig. 6A) . Among the genes examined, only the sterol regulatory element-binding protein (SREBP)-2 gene significantly increased in the SHL-YP group (P < 0:05). Considering the large variation of plasma lipids in the SHL-C group and the SHL-YP group (Fig. 3B) , it was difficult to obtain statistically significant data, but some marked tendencies were observed. CYP7A1 gene expression slightly increased in the SHL-YP group, and gene expression of the small heterodimer partner (SHP, a repressor for the transcription of CYP7A1), and farnesoid X receptor (FXR, a nuclear receptor for bile acid and a regulator of SHP), 23) also tended to decrease in the SHP-YP group. On the other hand, there was a decrease in expression of the liver X receptor (LXR) genes (P ¼ 0:056) in the SHL-YP group, and the SREBP-1, fatty acid synthetase (FAS), and stearoylCoA desaturase-1 (SCD-1) genes (the downstream genes of the LXRs) showed the same tendency. 7) Expression of the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR) gene, which is regulated by SREBP-2, also tended to increase in the SHL-YP group (P ¼ 0:092).
LDL receptor (LDL-R) gene expression, which is regulated preferentially by SREBP-2, has been reported to increase when bile acid-binding resins are given. [24] [25] [26] In this study, we found significant increases in fecal bile acid and hepatic SREBP-2 gene expression under YP treatment, but hepatic LDL-R gene expression did not change. To identify changes in expression at the protein level, we performed Western blot analysis for LDL-R (Fig. 6B) hepatic LDL-R protein levels, indicating that neither mRNA nor protein levels of hepatic LDL-R changed in the SHL-YP group.
Discussion
Generally, mice have the ability to clear hepatic LDL rapidly, resulting in a total serum cholesterol level of approximately 85 mg/dl, carried mostly as HDL.
11)
Hence, in investigating hyperlipidemia and atherosclerosis using mice, diet-dependent and genetic experimental models have been used. Among the genetic experimental models, the gene-targeted apoE-deficient mouse is particularly popular.
11) SHL mice are also apoE-deficient, and their dyslipidemic phenotypes, including high plasma lipoprotein cholesterols, xanthoma, and atherosclerosis, have been identified by Matsushima et al. 10, 12) The present study also found that C57BL/ 6.KOR-ApoE shl mice have higher hepatic cholesterol and triglyceride levels, higher plasma lipoprotein cholesterols (except for HDL cholesterol), and lower plasma HDL cholesterol than C57BL/6.Cr mice. SHL mice are therefore useful as a model of hyperlipidemia, in the same manner as gene-targeted apoE-deficient mice.
In the present study, we identified a hypolipidemic effect of YP on the genetically determined hyperlipidemia of C57BL/6.KOR-ApoE shl mice. All plasma lipoprotein cholesterols, except for HDL cholesterol, and plasma triglyceride decreased significantly in the SHL-YP group. Among the decreased lipoprotein cholesterols, VLDL cholesterol showed the largest decrease (SHL-C, 405:87 AE 112:90; SHL-YP, 226:45 AE 68:69). VLDL is a lipoprotein subclass assembled in the liver, and it is catabolized to LDL in the circulation. The catabolic process from VLDL to LDL fails in SHL mice because of apoE deficiency, leading to a high cholesterol content in the plasma, mostly in the form of VLDL (or in intermediate-density lipoprotein, IDL). On the other hand, fecal bile acid was 1.6-fold higher in the SHL-YP group than in the SHL-C group (5:55 AE 0:67 vs. 3:42 AE 0:27 mmol/2 d). The hepatic biosynthesis of bile acids from cholesterol is a major pathway in the catabolism and removal of cholesterol from the body, and this mechanism is exploited by hypolipidemic agents, such as bile acid-binding resins. Although the rate of increase in fecal bile acid under YP treatment (1.6-fold) appeared to be low, the amount (5.55 mmol/2 d) might be enough to influence cholesterol homeostasis. Bile acid-binding resins have been reported to de-repress CYP7A1 activity and to induce hepatic LDL-R expression, resulting in stimulation of plasma LDL clearance, followed by plasma LDL reduction. 26) A slight increase in hepatic CYP7A1 gene expression was observed under YP treatment, but neither mRNA nor protein levels of hepatic LDL-R changed in the SHL-YP group, indicating that the hypolipidemic effect due to YP in C57BL/ 6.KOR-ApoE shl mice did not depend on the capacity for hepatic LDL-R. The increase in fecal bile acid excretion and the large decrease in plasma VLDL cholesterol under YP treatment suggest that acceleration of fecal bile acid excretion is a major mechanism of the hypolipidemic effect induced by YP in C57BL/ 6.KOR-ApoE shl mice. In contrast to the reduced plasma triglyceride level, the livers of the SHL-YP group unexpectedly contained increased amounts of triglyceride, and the histopathology also indicated an increase in lipid accumulation. A similar result has also been reported in SREBP-2 transgenic mice. 24) Liver triglyceride content was significantly higher in SREBP-2 transgenic mice than in wild-type mice, whereas the plasma triglyceride level of the transgenic mice tended to be lower. The SHL-YP group also showed significant increases in the hepatic SREBP-2 gene, suggesting that YP treatment induces the same or similar events as SREBP-2 transgenic mice in the liver.
Our previous study indicated that YP intake prevented fatty liver in a diet-induced murine obesity model, 15) and this result was reproduced in our laboratory (data not shown). Considering the liver histopathology (without large lipid droplets, inflammation, or fibrosis) and the plasma glucose level, the increase in lipid accumulation to the liver appeared to cause little damage to the SHL-YP group in comparison to the SHL-C group, while YP certainly promoted hepatic lipid accumulation in the C57BL/6.KOR-ApoE shl mice. The discrepancy between the present and previous results is unexplained, but this hepatic lipid accumulation might be specific to the C57BL/6.KOR-ApoE shl strain. Although significant beneficial effects on plasma lipid levels were caused by YP treatment in the C57BL/6.KOR-ApoE shl mice, a statistical significance in hepatic gene expression was unexpectedly observed only for the SREBP-2 gene among the genes examined. Our previous study showed significant increases in CYP7A1 gene expression in the liver (3-fold, P < 0:05) by a 14-week administration of 10% YP, 15) The genes related to lipid metabolism were examined by real-time RT-PCR (A). Elongation factor-1 was used as a control to standardize the efficiency of each reaction. The results represent the mean AE SE. Statistical significance was observed for expression of the SREBP-2 gene by unpaired t-test (P < 0:05). Western blot analysis for LDL-R protein in the liver (B). LDL-R protein is detected as broad bands from 100 to 160 kDa because of its highly glycosylated form. Beta-actin was used as the internal control.
slight increase (1.3-fold) in the CYP7A1 gene expression was induced in the SHL-YP group, without statistical significance, in this study. Considering the difference in the amount of YP supplementation to the diet, 5% YP might be not enough to induce a significant increase in expression of the CYP7A1 gene. The hepatic LXRs genes decreased in the SHL-YP group (P ¼ 0:056). LXR belong to the intracellular receptor superfamily of ligand-activated transcription factors, and two subtypes, LXR and LXR, have been identified. 27) LXRs regulate a number of genes related to reverse cholesterol transport, lipid metabolism, and inflammatory signals, and their agonists can activate these genes. 27, 28) Transcriptional factor SREBP-1 is a gene regulated by LXRs, and activated SREBP-1 protein regulates lipogenic enzyme genes, such as FAS and SCD-1. [27] [28] [29] It has been reported that LXRs agonists induce hypertriglycemia and hepatic steatosis due to induction of SREBP-1 and FAS genes in the liver. 30) Hence, the hepatic down-regulation of LXRs genes by YP might have contributed to the decrease in plasma triglyceride. LXRs also regulate the ATP binding cassette transporter A1 (ABCA1) gene. ABCA1 mediates the efflux of excess cholesterol and phospholipids from peripheral cells and contributes a rise in plasma HDL. 28) This indicates that decreases in LXRs genes might cause down-regulation of ABCA1, leading to a slight decrease in plasma HDL cholesterol in the SHL-YP group. On the other hand, SREBP-2 regulates hepatic cholesterogenic genes, such as HMGCoAR and LDL receptor. 24, 25) Horton et al. found that SREBP-2 transgenic mice showed more marked increases in hepatic gene transcription of HMGCoAR (75-fold) than that of the LDL-R (5.8-fold), 24) indicating that HMGCoAR transcription was more sensitively regulated by SREBP-2 than LDL-R transcription. The same sensitivity to expression of the HMGCoAR gene was observed in this study (P ¼ 0:092). Together with an increase in expression of the SREBP-2 gene (1.3-fold) in the SHL-YP group, expression of the HMGCoAR gene also increased by 1.6-fold, suggesting that YP treatment induced hepatic SREBP-2 expression and activation.
Our previous study indicated that mature persimmon fruit (MP) did not improve lipid metabolism in a dietinduced murine obesity model. 15) In a comparison of constituents between YP and MP, effective YP contains larger amounts of tannin (YP, 14.7%; MP, 3.2% w/w, as analyzed by the Folin-Denis method) and dietary fiber (YP, 44.9%; MP, 20.2% w/w, as analyzed by the Prosky method) than ineffective MP, suggesting that tannin and dietary fiber in YP might contribute its hypolipidemic effect individually, synergistically, or additively. A search for functional constituents of YP is currently under way in our laboratory.
In summary, the present study indicated that YP ameliorates hyperlipidemia in apoE-deficient C57BL/ 6.KOR-ApoE shl mice, which is consistent with our previous study with a diet-induced murine obesity model. Hence YP might be a beneficial food material or agent for prevention of and therapy for hyperlipidemia.
